CORONA, Calif. (AP) -- Watson Pharmaceuticals said Monday that it is being sued by Biovail Corp. after it sought federal approval for a generic version of that company's anti-depression drug.
Biovail filed suit in U.S. District Court for the District of Delaware, claiming patent infringement. The lawsuit would stop the Food and Drug Administration from making a final decision on a generic version of Aplenzin ER for up to 30 months.
Shares of Watson Pharmaceuticals Inc. rose 6 cents, or 0.15 percent, to $39.17.
